The International Legal Responsibility of Pharmaceutical Companies for Human Rights Violations
https://doi.org/10.24833/0869-0049-2014-2-4-20
Abstract
The pharmaceutical sector plays an important role in ensuring the right to health by creating conditions for access to medicines. However, the policy and practice of a number of big pharmaceutical companies creates additional problems for the States in realisation of citizens’ rights to the highest attainable standard of health and as a result interferes with their efforts to ensure access to medicines. In contemporary international law there are virtually no provisions allowing making pharmaceutical companies accountable for human rights violations. However, in a growing number of human rights violations on the part of pharmaceutical companies and the lack of effective national legal remedies, the need of an effective international mechanism, which will take into account the national experience acquired in this fi eld and make pharmaceutical companies accountable for violations of human rights, becomes increasingly apparent.
About the Authors
Aslan H. Abashidze
Russian Peoples’ Friendship University
Russian Federation
Russian Federation
Vladislav S. Malichenko
MGIMO-University MFA Russia
Russian Federation
Russian Federation
References
1. Маличенко В.С. Обращение лекарственных средств - элемент стратегии национальной безопасности США Обозреватель №7, 2013 стр. 80-91
2. J.A.Dimassi, “The price of innovation: New estimates of drug development Costs”, Journal of Health Economics 22 №2, March 2003: p. 151-185.
3. J. Love, “IRS Data Shows Drug Industry Cost Estimates Exaggerated,” Knowledge Economy International news release, Washington D.C, November 30, 2001.
4. G.Foster, “Opposing Forces in s Revolution in International Patent Protection: The U.S. and India in the Uruguay Round and its Aftermath” UCLA Journal of International Law and Foreign Affairs.
5. Leaf С., «The Law of Unintended Consequences», Fortune, September 19, 2005.
6. Goozner M. The $800 million pill: the truth behind the cost of new drugs. Berkley: University of California Press; Press 2005.
7. Stevens A.J., Jensen J.J., Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine. 2011; 364: 535-41.
8. Boseley S. Scandal of scientists who take money for papers ghostwritten by the drug companies. The Guardian. 2002. Feb 7.
9. Ross D.B. The FDA and the case of Ketek. New England Journal of Medicine.2007; 356: 1675-6.
10. Day M. Italian police arrest drug offi cials over alleged falsifi cation on data. BMJ. 2008; 336: 1208-9.
11. Lurie P., Wolfe S.M. FDA medical offi cers report lower standards permit dangerous drug approvals. Public citizen. 1998.
12. Willman D. Diabetes Drug rezulin pulled off the market. Los Angeles Times. March. 2000.
13. Bailey R.S. FDA corruption charges letter verifi ed. The Los Angeles Post. 2012 April 8.
14. Xi.Yu. Three Professors face sanctions following Harvard medical school inquiry. Harvard crimson. 2011.
15. Special Rapporteur of the Commission on Human Rights on the Right to the Enjoyment of the Highest Attainable Standard on Physical and Mental Health. UN Doc. A/HRC/11/12/ ADD.2 (2009).
16. Абашидзе А.Х., Маличенко В.С. Обеспечение доступа к лекарственным средствам в условиях развития механизмов защиты прав интеллектуальной собственности. Современное право №7. 2013. Cтр. 155-157.
17. G.Harris «Prilosec’s Maler Switches Users to Nexium, Thwarting Generics», Wall street Journal, June 6, 2002
18. Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft skull press. 2006.
19. Rockoff J.D., Matthews C.M. Pfi zer settles federal bribery investigation. Wall street journal. 2012 Aug 7.
20. Kelton E. J&J needs a cure: new CEO allegedly had links to fraud. Forbes 2012 19 April
21. http://www1.umn.edu/humanrts/russian/links/Rnorms-Aug2003.html.
Review
For citations:
Abashidze A.H., Malichenko V.S. The International Legal Responsibility of Pharmaceutical Companies for Human Rights Violations. Moscow Journal of International Law. 2014;2(2):4-20. (In Russ.) https://doi.org/10.24833/0869-0049-2014-2-4-20
Views:
827
Email this article 